In Reply

Authors:

Abstract
The United Kingdom Obstetric Surveillance System (UKOSS) report was published after we had finished collecting data and shortly before we submitted our manuscript to ANESTHESIOLOGY.1,2 We apologize for the oversight; we certainly would have contacted Knight had we been aware of UKOSS at that time. However, it is unclear how many of the cases in the UKOSS database would have qualified for our review. We employed the traditional definition of amniotic fluid embolism (AFE) used by the United Kingdom AFE register and the United States AFE registry.3,4 Patients had to have at least one major cardiac and one major pulmonary symptom (or cardiopulmonary arrest) plus consumptive coagulopathy to be diagnosed with AFE. In contrast, UKOSS used a much broader definition of AFE; for example, 38% of the UKOSS AFE patients did not have a coagulopathy.1 This is not a trivial distinction, for patients who do not meet the traditional definition of AFE seem to have better outcomes after receiving recombinant factor VIIa (rVIIa) than patients who do meet the definition, as seen in these case reports.5,6 We believe that the broader definition of AFE used by UKOSS permitted the enrollment of patients with similar but different diseases.

This publication has 4 references indexed in Scilit: